Skip to main content

Dr. Hani M. Babiker, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
26
In the NPI registry since
2008
Medicare patients seen, 2024
701

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    FL license ME142546
  • Hospitalist Physician
    AZ license 42076
  • Internal Medicine Physician
    NY license 250230

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
701
Services billed
114,053
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram14,82022
Injection, nivolumab, 1 mg10,56021
Injection, pembrolizumab, 1 mg10,00037
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)9,18018
Injection, fosaprepitant, 1 mg8,25044
Injection, daratumumab, 10 mg and hyaluronidase-fihj7,38025
Injection, darbepoetin alfa, 1 microgram (non-esrd use)6,82516
Injection, oxaliplatin, 0.5 mg5,00016
Injection, paclitaxel, 1 mg4,00218
Injection, denosumab, 1 mg3,18027

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 20 payments worth $8,439 in total to this clinician.

By company
Ipsen Biopharmaceuticals, Inc$6,401
Novocure Inc.$2,037
By type
Consulting Fee$6,090
Travel and Lodging$1,298
Food and Beverage$1,051

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 21, 2025Ipsen Biopharmaceuticals, Inc
Feb 21, 2025
Consulting Fee$3,480
Jan 9, 2025Ipsen Biopharmaceuticals, Inc
Jan 9, 2025
Consulting Fee
Onivyde · Oncology
$2,610
Oct 30, 2025Novocure Inc.
Oct 30, 2025
Travel and Lodging
travel to Dallas, TX
$906
Nov 8, 2025Novocure Inc.
Nov 8, 2025
Travel and Lodging
travel to Dallas, TX
$368
Nov 9, 2025Novocure Inc.
Nov 9, 2025
Travel and Lodging
travel to Dallas, TX
$20.93
Oct 30, 2025Novocure Inc.
Oct 30, 2025
Travel and Lodging
travel to Dallas, TX
$3.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $730,564 in research payments for these studies, mostly to the institutions running them.

  • Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
    E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05245500
  • Tumor Treating Fields Effect on Pancreatic Adenocarcinoma Desmoplastic Tumor Microenvironment and Therapeutic Impact
    Novocure GmbH
  • A study of KK2269 in adult participants with solid tumors
    Kyowa Kirin Co., Ltd
  • NOVOTTF-100L -a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy …
    Novocure Inc.
  • A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
    AstraZeneca Pharmaceuticals LP
  • EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
    Novocure Inc.
  • Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
    Genentech, Inc.
  • A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer wit…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Un…
    Incyte Corporation
  • A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patien…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Jacksonville

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 23, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1801055595. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.